# Trellis Bioscience

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/trellis-bioscience

- Industry: Biotechnology
- Headquarters: Redwood City, US
- Website: www.trellisbio.com/
- Total disclosed funding: $24M
- Latest round: Series C (Jul 16, 2026)
- Investors on record: 9

## About

Trellis Bioscience, Inc. is a US-based biopharmaceutical company focused on developing monoclonal antibody therapies that target infectious diseases, particularly prosthetic joint infections, respiratory syncytial virus, and human cytomegalovirus. Founded in 2001 and headquartered in Redwood City, US, Trellis Bioscience specializes in monoclonal antibody therapy development. In July 2026, Trellis Bioscience, Inc. raised USD 9 million in series C funding from New Science Ventures, AMR Action Fund, The Doctor Group of Dallas and Easton Capital Investment Group. The company was founded by Larry Kauvar and Stote Ellsworth, with CEO Stefan Ryser currently at the helm. Trellis Bioscience specializes in developing innovative monoclonal antibody (mAb) therapies targeting infectious diseases. Its lead product, TRL1068 (calpurbatug), is currently in Phase 1 clinical trials. The company utilizes its proprietary CellSpot™ platform for rapid discovery of high-affinity mAbs from human memory B-cells, enhancing therapeutic efficacy. Its product pipeline addresses viral infections caused by HCMV, RSV, and influenza, catering to global health markets. Trellis Bioscience generates revenue primarily through partnerships and collaborations in the biopharmaceutical sector, focusing on clinical studies and the development of monoclonal antibody therapies. The company engages in transactions with pharmaceutical companies and healthcare institutions for research and development initiatives. Revenue is also derived from agreements related to its CellSpot™ technology. Specific pricing details are not disclosed, but transactions align with industry standards, involving clinical development milestones and potential royalties from successful mAb commercialization.

The company will use the July 2026 funding to advance its ongoing Phase II clinical study of calpurbatug, a monoclonal antibody candidate for chronic PJI.

## Funding rounds

- Series C, Jul 16, 2026, $9M — Easton Capital Investment Group, New Science Ventures, AMR Action Fund, Doctor Group of Dallas
- Series C, Jul 14, 2009 — Morgenthaler Ventures, Novartis Venture Fund, Easton Capital Investment Group
- Series B, Feb 8, 2007, $10M — Morgenthaler Ventures, Novartis Venture Fund, Easton Capital Investment Group, Pac-Link, Sagamore Investments
- Series A, Oct 24, 2005, $5M — Forward Ventures, Easton Capital Investment Group

## Investors

- Forward Ventures (https://capitalatlas.ai/funds/forward-ventures) — Series A
- Easton Capital Investment Group (https://capitalatlas.ai/funds/easton-capital-investment-group) — Series A, Series B, Series C
- Morgenthaler Ventures (https://capitalatlas.ai/funds/morgenthaler-ventures) — Series B, Series C
- Novartis Venture Fund (https://capitalatlas.ai/funds/novartis-venture-fund) — Series B, Series C
- Pac-Link (https://capitalatlas.ai/funds/pac-link) — Series B
- Sagamore Investments — Series B
- New Science Ventures (https://capitalatlas.ai/funds/new-science-ventures) — Series C
- AMR Action Fund (https://capitalatlas.ai/funds/amr-action-fund) — Series C
- Doctor Group of Dallas — Series C